Vaccinex, Inc. Announces 1-for-14 Reverse Stock Split to Secure Nasdaq Compliance
ROCHESTER, N.Y. – In a strategic maneuver to retain its Nasdaq listing and meet the minimum bid price requirement, Vaccinex, Inc. (NASDAQ: VCNX), a front-runner clinical-stage biotech company specializing in neurodegenerative diseases and cancer treatments, has announced a significant 1-for-14 reverse stock split of its issued common stock, set to take effect post-market close on Monday, February 19, 2024.
Exclusive Access: Unlock Premium, Confidential Insights
Unlock This Exclusive Content—Subscribe Instantly!
Login if you have purchased
